Background {#Sec1}
==========

Thalassemia (thal) is one of the most common inherited blood disorder in the world. This disease caused by reduced or/and absent synthesis of the globin chains of hemoglobin (Hb), which leading to imbalance of the globin chains \[[@CR1], [@CR2]\]. Beta-thalassemia (β-thal) is one of the major types of thalassemia and it results from decrease in lack of beta-globin (β-globin) chain production \[[@CR3]\]. Thalassemia intermedia (TI) or non-transfusion-dependent thalassemia (NTDT) is a moderate clinical form of the β-thal disease.

It has a broad clinical spectrum, spanning in severity from asymptomatic thalassemia minor to transfusion-dependent thalassemia major (TM) phenotype \[[@CR4]\]. Thalassemia intermedia can result from the inheritance of one or two β-thal alleles \[[@CR5]--[@CR8]\]. On the other hand, no clinical significance have been observed for delta-globin (δ-globin) gene mutations, but this gene has important relevance for the screening of β-thal carriers \[[@CR9]\]. Hemoglobin A2 (Hb A2), is a minor adult hemoglobin, its levels ranged between (2--3.2%) of the total circulating haemoglobin in healthy adults \[[@CR10]\]. The increase in Hb A2 level more than borderline levels is the most important parameter for the identification of thalassemia carriers \[[@CR2]\]. The presence of δ-thal mutation, however, interferes with this typical β-thal phenotype, affecting population screening programs for β-thal carriers. Delta/beta-thalassemia (δβ-thal) is as a consequences of a deletion in both the delta and beta genes on chromosome 11. This deletion leads to increase of production of gamma globin (*y*-globin) gene, which increases the amount of fetal hemoglobin (Hb F). The δβ-thal heterozygotes clinically display characteristics of thalassemia minor. However, homozygous δβ-thal state could appear a clinical description of thalassemia intermedia (TI) with a mild anemia \[[@CR11]\]. Some genome-wide association studies have reported that there are at least three major loci that play a major role in increasing Hb F levels \[[@CR12]\]. One of them, is the − 158 C \> T (HBG2: c.-211C \> T) in the promoter gene Gamma 2 (locus XmnI). This locus simultaneously has an influence on up to 20--50% of Hb F variation in patients with β-thal or in healthy adults \[[@CR13]\].

Here, we report a β-thal affected proband with low level of Hb A2 who had point mutation in codon 5 \[−CT\] combined with Hb Knossos codon 27 (G \> T) on the β-globin gene associated with codon 59 \[−A\] mutation on the δ-globin gene. To the best of our knowledge, this is the first report which described the Hb Knossos /codon 5 \[−CT\] genotype associated with δ-thal mutations in Syrian patient.

Case presentation {#Sec2}
-----------------

12-year-old male proband, was referred to our center AECS- in Damascus for confirmation of his affected status for β-thalassemia. The parents were non-consanguineous. His history revealed, pallor and anemia. The electropherogram revealed low level of (Hb A1) 36.2%, high level of (Hb F) 62.2% and low level of (Hb A2) 1.6%, for that, δ-globin gene variant was suspected. His father had a classical clinical picture of β-thalassemia trait. His mother had normal indices but with reduced (Hb A2 levels) 1.9%, all hematological data were summarized in Table [1](#Tab1){ref-type="table"}. The parents had never been transfused, while the proband requires blood transfusion occasionally.Table 1The hematological and molecular data of the familyParametersProband's FatherProband's MotherProbandSex-age (years)M-40F-38M-12Hb (g/dL)11.2149RBC (10^12^/L)5.45.54.2MCV (fL)60.428364MCHC (g/dl)31.532.233.9MCH (pg)19.3527.321.8RDW-CV (%)14.915.618Hb A1 (%)93.298.136.2Hb A2 (%)3.81.91.6Hb F (%)3062.2α Genotypeαα/αααα/αααα/ααβ Genotypeβ ^A^/β ^codon\ 5\[−CT\]^β ^A^/β ^Hb\ Knossos^β ^codon\ 5\[−CT\]^ /β ^Hb\ Knossos^δ Genotypeδ ^A^/δ ^A^δ ^A^/δ ^Codon\ 59\ (−A)^δ ^A\ /\ Codon\ 59\ (−A)^*RBC* red blood cell count, *Hb* hemoglobin, *MCV* mean corpuscular volume, *MCH* mean corpuscular *Hb*, *RDW-CV* RBC distribution width- coefficient of variation.

To investigate the high level of Hb F in the proband, the XmnI restriction site at − 158 position of the ^G^γ-gene was done. Hematological parameters of the parents and proband were obtained with an automated differential cell counter (ABX Micros ES60; HORIBA ABX SAS, Montpellier, France). Capillary Hemoglobin electrophoresis (Hb) analysis were measured using Capillarys 2 system (Sebia, Lisses, France) system.

After obtaining informed consent, genomic DNA was isolated from peripheral blood from the parents and proband using the QIAamp DNA Blood Mini kit (Qiagen, Germany) according to the manufacturer's instructions. Purified gDNA was run on a 0.8% agarose gel. The quality and quantity of the DNA was determined spectrophotometrically (NanoVue™; GE HealthCare, Freiburg, Germany).

Direct DNA sequencing of the entire human HBB and HBD genes was done on an ABI PRISM 310-DNA Analyzer (Applied Biosystem, Foster City, CA, USA) as previously reported \[[@CR14], [@CR15]\]. The genotyping of HBB gene was determined by polymerase chain reaction (PCR). The suitable primers were used for three exons of β-globin gene including the promoter, first intron, 5' and 3' untranslated region (UTR) sequences as previously reported \[[@CR16]\]. For HBD gene, two specific primer sets were designed for Ex 1& 2 and Ex 3 including their flanking regions on the δ-globin gene as previously reported \[[@CR17]\]. Reverse hybridization assay (α-Globin StripAssay® 4--160; ViennaLab Diagnostics Gmb Vienna, Austria) which covers 21 of α-thal mutations was used according to the manufacturer's instructions. Detection of Xmn-I locus was performed with RFLP-PCR technique with specific primers and restriction enzyme Xmn-I \[[@CR13]\].

In this case, the blood and physical examination of the proband showed that, and he had anemia and pallor, and he was affected by delta and beta thalassemia. Hematological and molecular data for the family were described in Table [1](#Tab1){ref-type="table"}. Direct DNA sequencing for β-globin and δ-globin genes shown in Fig. [1](#Fig1){ref-type="fig"}. The father had the β^0^ Codon 5 \[−CT\] mutation in heterozygous state, whereas, the mother presented the β^+^ Hb Knossos codon 27 (G \> T) mutation with δ^0^ codon 59 \[−A\] mutation both in heterozygous state, thus resulting in a low level of Hb A2 (1.9%) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Direct sequencing analysis revealed the PCR fragment on the δ-globin and β-globin genes. (A), (C~1~) the arrows indicates the \[−CT\] deletion at codon 5 in the β-globin gene for the father and the proband respectively; (B~1~), (C~2~) the arrows indicates the \[−A\] deletion at the codon 59 in the δ-globin gene for the mother and the proband respectively; (B~2~), (C~3~) the arrows indicates the Hb Knossos substitution at the codon 27 in the β-globin gene for the mother and the proband respectively

The Molecular analysis of the proband showed that, he had inherited the β^0^ codon 5 \[−CT\] mutation from his father, and had inherited the β^+^ Hb Knossos codon 27 (G \> T) mutation and the δ^0^ codon 59 \[−A\] mutation from his mother, so, a low level of Hb A2 (1.6%) was also observed (Fig. [1](#Fig1){ref-type="fig"}). On the other hand, the results of the α-thal test in the proband revealed that none of the common deletional forms were present.

The result of PCR/RFLP of the Xmn-I locus at − 158 to the ^G^훾-globin gene indicated that, the homozygosity \[TT\] genotype in the proband was observed.

Discussion and conclusions {#Sec3}
==========================

Hb Knossos is a rare Hb variant in the world, it was first described in a Greek family \[[@CR18]\]. The β^+^ Hb Knossos, codon 27 (G \> T) (HBB: c.82G \> T, p.Ala28Ser) activates a cryptic splice site in the β-globin gene which competes with the normal splice site thereby resulting in reduced production of Hb Knossos mRNA \[[@CR19]\]. It is described to produce the classical phenotype of β-thal intermedia in association with β^0^-thal trait. Also, it has been reported in combination with different β-thal mutations like IVS-I-1 (G \> A) \[[@CR20]\] and IVS-I-110 (G \> A) \[[@CR21]\] causing a moderate phenotype, whereas its association with the IVS-II-745 (C \> G) resulted in a major phenotype \[[@CR22]\]. The β^0^ Codon 5 \[−CT\] mutation was well-known to complete inhibition of β-chain synthesis through the formation of a premature termination signal at codon 21. In our case, the combination of β^+^ Hb Knossos with β^0^ codon 5 \[−CT\] mutation is reported for the first time, and it leads to β-IT phenotype.

The δ-globin gene mutations have no clinical implication. However, the co-inheritance of δ-globin gene variant with β-thal may camouflage the β-thal carrier status by decreasing the Hb A2 levels \[[@CR11], [@CR23], [@CR24]\]. The codon 59 \[−A\] mutation is one of the rare δ^0^-globin gene mutation, it deletes a single A in codon 59 leading to premature termination in codon 60. Hb Knossos mutation was reported to be linked to δ^0^-globin gene codon 59 \[−A\] mutation in the majority of North African and Mediterranean countries \[[@CR25]--[@CR27]\]. This combination correlated to normal or borderline red blood cell indices and also with low Hb A2 levels \[[@CR25], [@CR28]\]. In this study, the δ^0^ codon 59 \[−A\] mutation was observed for the first time in a Syrian family, and it was associated with the β^+^ Hb Knossos mutation for the proband and mother. In addition, a coinheritance of β^0^ codon 5 \[−CT\] mutation with δ^0^ codon 59 \[−A\] mutation was observed for the proband. Two mutations shown to be inherited *in trans*, the proband inherited the β^0^ codon 5 \[−CT\] mutation from his father and the δ^0^ codon 59 \[−A\] mutation from his mother. On the other hand, the level of Hb F was (62.2%) for the proband, and the genotype of Xmn-I polymorphism was homozygous \[TT\]. This factor may be contributed to produce a high level of Hb F as previously reported \[[@CR29], [@CR30]\].

In conclusion, we present here a case of rare β^+^ Hb Knossos codon 27 (G \> T) variant associated with β^0^ codon 5 \[−CT\] mutation in β-globin gene and δ^0^ codon 59 \[−A\] mutation in δ-globin gene which were found in Syrian male proband for the first time in a Syrian family. However, As Syria is one of the countries where β-thal is prevalent, δ-thal mutations should be investigated at the β-thal carriers when we have low level of Hb A2, due to interactions between these haemoglobinopathies which can failing to diagnose the β-thalassemia carriers.
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